Skip to content

Find AMD Even Before Clinical Signs Appear with the Help of AdaptDx

Robert Hamilton

Robert Hamilton from Moorfields Eye Hospital talks about his experience with the AdaptDx dark adaptometer. Its high sensitivity, specificity, and reproducibility enable physicians to find AMD even before clinical signs appear and subsequently monitor the progression of the disease and the effectiveness of treatment.

Back to Videos

 

Transcript:

I think one of the most important things from my point of view is trying to catch the AMD patients before it gets to end stage. So how do you catch somebody before they become neovascular, before they get significant geographic atrophy? How you monitor the intervention is really important and one of the best ways to a monitor intervention is focal flash recovery, other electro diagnostic tests but the focal flash recovery is a really good way of monitoring retinal function and the changes within retinal function that any intervention could produce.

An advantage of the AdaptDx is its sensitivity, its specificity, and its reproducibility

We’ve used the AdaptDx and more fields for a number of studies. Really, it’s just been very early stages looking at early an intermediate AMD and making sure it’s reproducible. If you get a reproducible test for these patients then you can accurately monitor what you are doing with any intervention. You can watch their natural history and you can then watch the result of any intervention. What I think one of the advantages of it is its sensitivity, its specificity, and its reproducibility. I think that’s one of the greatest things. We’ve used a number of other products and I think this is probably one of the best ones on the market at the moment. It’s fairly straightforward, patient acceptability is good, and so I think the reproducibility for me is part of the most important. Once you get to the end stage, so once you get to geographic atrophy or CNV, we know that although the treatments that we have available for CNV are good, in general people still continue to lose vision. So if we can actually stop people getting geographic atrophy that’d be really valuable. I think we are getting to a stage now where there are a number of interventions. The most obvious intervention is vitamin supplementation for early AMD. The AdaptDx could not only highlight the people who have got early AMD, probably better than before you would see anything clinically, but also can then monitor the effect of anything that you’re using. Interventions that we’ve been trialing such as the 2RT or even the 670-nanometer exposures could potentially benefit our patients and how do you monitor that appropriately? The AdaptDx is probably the best way to do that.